Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam
Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K. pneumoniae isolates were collected from 16 sites in 5 regions across China during 2019....
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716525001146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335380630831104 |
|---|---|
| author | Peiyao Jia Pengcheng Li Wei Yu Xiaobing Chu Hui Zhang Jingjia Zhang Wei Kang Ge Zhang Qian Zhang Shiyu Chen Yingchun Xu Qiwen Yang |
| author_facet | Peiyao Jia Pengcheng Li Wei Yu Xiaobing Chu Hui Zhang Jingjia Zhang Wei Kang Ge Zhang Qian Zhang Shiyu Chen Yingchun Xu Qiwen Yang |
| author_sort | Peiyao Jia |
| collection | DOAJ |
| description | Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K. pneumoniae isolates were collected from 16 sites in 5 regions across China during 2019. Antimicrobial susceptibility testing was performed. For IPMNS K. pneumoniae isolates, whole genome sequencing was used to screen for drug-resistance and virulence genes. Results: Of 1011 clinical K. pneumoniae isolates, 277 (27.3%) were IPMNS and were significantly more common in intensive care unit patients (47.5%) and hospital-acquired infections (28.9%). Production of carbapenemase was the dominant resistance mechanism, with 228 (89.8%) IPMNS isolates harbouring blaKPC-2, 8 (3.1%) blaNDM, 2 (0.8%) blaOXA-232 and 1 (0.4%) blaOXA-181. The dominant clone was sequence type (ST) 11 (78.7%) followed by ST15 (10.2%). Relebactam restored imipenem’s susceptibility in 96.5% isolates harbouring a blaKPC-2 gene. Conclusions: Harbouring the blaKPC-2 gene was the dominant mechanism of IPMNS K. pneumoniae in China. Empirical imipenem/relebactam treatment could be considered when susceptibility or carbapenemase tests are not available. |
| format | Article |
| id | doaj-art-e31b250ada0c4aaf92c970ec3356989c |
| institution | Kabale University |
| issn | 2213-7165 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj-art-e31b250ada0c4aaf92c970ec3356989c2025-08-20T03:45:18ZengElsevierJournal of Global Antimicrobial Resistance2213-71652025-09-01441710.1016/j.jgar.2025.05.011Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactamPeiyao Jia0Pengcheng Li1Wei Yu2Xiaobing Chu3Hui Zhang4Jingjia Zhang5Wei Kang6Ge Zhang7Qian Zhang8Shiyu Chen9Yingchun Xu10Qiwen Yang11Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaValue & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding author. Mailing address. Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Street, Beijing 100730, China.Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K. pneumoniae isolates were collected from 16 sites in 5 regions across China during 2019. Antimicrobial susceptibility testing was performed. For IPMNS K. pneumoniae isolates, whole genome sequencing was used to screen for drug-resistance and virulence genes. Results: Of 1011 clinical K. pneumoniae isolates, 277 (27.3%) were IPMNS and were significantly more common in intensive care unit patients (47.5%) and hospital-acquired infections (28.9%). Production of carbapenemase was the dominant resistance mechanism, with 228 (89.8%) IPMNS isolates harbouring blaKPC-2, 8 (3.1%) blaNDM, 2 (0.8%) blaOXA-232 and 1 (0.4%) blaOXA-181. The dominant clone was sequence type (ST) 11 (78.7%) followed by ST15 (10.2%). Relebactam restored imipenem’s susceptibility in 96.5% isolates harbouring a blaKPC-2 gene. Conclusions: Harbouring the blaKPC-2 gene was the dominant mechanism of IPMNS K. pneumoniae in China. Empirical imipenem/relebactam treatment could be considered when susceptibility or carbapenemase tests are not available.http://www.sciencedirect.com/science/article/pii/S2213716525001146Klebsiella pneumoniaeImipenem/relebactamImipenem non-susceptibleEpidemiology |
| spellingShingle | Peiyao Jia Pengcheng Li Wei Yu Xiaobing Chu Hui Zhang Jingjia Zhang Wei Kang Ge Zhang Qian Zhang Shiyu Chen Yingchun Xu Qiwen Yang Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam Journal of Global Antimicrobial Resistance Klebsiella pneumoniae Imipenem/relebactam Imipenem non-susceptible Epidemiology |
| title | Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam |
| title_full | Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam |
| title_fullStr | Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam |
| title_full_unstemmed | Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam |
| title_short | Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam |
| title_sort | clinical imipenem non susceptible klebsiella pneumoniae isolates from china epidemiology molecular characterization and in vitro activity of imipenem relebactam |
| topic | Klebsiella pneumoniae Imipenem/relebactam Imipenem non-susceptible Epidemiology |
| url | http://www.sciencedirect.com/science/article/pii/S2213716525001146 |
| work_keys_str_mv | AT peiyaojia clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT pengchengli clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT weiyu clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT xiaobingchu clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT huizhang clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT jingjiazhang clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT weikang clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT gezhang clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT qianzhang clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT shiyuchen clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT yingchunxu clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam AT qiwenyang clinicalimipenemnonsusceptibleklebsiellapneumoniaeisolatesfromchinaepidemiologymolecularcharacterizationandinvitroactivityofimipenemrelebactam |